PMID- 34610704
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211022
IS  - 2287-1012 (Print)
IS  - 2287-1292 (Electronic)
IS  - 2287-1012 (Linking)
VI  - 26
IP  - 3
DP  - 2021 Sep
TI  - Efficacy and adverse events related to the initial dose of methimazole in 
      children and adolescents with Graves' disease.
PG  - 199-204
LID - 10.6065/apem.2142046.023 [doi]
AB  - PURPOSE: The first-line antithyroid drug for children and adolescents with 
      Graves' disease (GD) is methimazole (MMI). This study evaluated the relationship 
      between the initial MMI dose and the clinical course of GD after treatment. 
      METHODS: We studied the efficacy of the initial MMI dose and the relationship 
      between the initial MMI dose and adverse events (AEs). We retrospectively 
      enrolled 22 males and 77 females and divided those subjects into 3 groups 
      according to the initial dose of MMI: <0.4 mg/kg/day (group A; n=32); 0.4-0.7 
      mg/kg/day (group B; n=39); and >0.7 mg/kg/day (group C; n=28). RESULTS: The 
      mean time to the normalization of free thyroxine (fT4) levels upon initial 
      treatment was 5.64, 8.61, and 7.98 weeks in groups A, B, and C, respectively 
      (P=0.116). The incidence of liver dysfunction, neutropenia, and skin rash was 
      12.5%, 20.5%, and 42.9% in groups A, B, and C, respectively (P=0.018). 
      Neutropenia, as a severe AE, was absent in group A, but its prevalence was 7.7% 
      in group B and 21.4% in group C (P=0.015). When comparing only groups B and C, 
      the incidences of liver dysfunction and neutropenia were higher in group C 
      (P=0.04 and P=0.021, respectively). CONCLUSION: The mean time to the 
      normalization of fT4 levels did not differ among the 3 groups, but the incidence 
      of AEs was higher in the groups that received high MMI doses. High doses of MMI 
      (>0.7 mg/kg/day) should be reconsidered as an initial treatment for children 
      and adolescents with GD.
FAU - Lee, Hyun Gyung
AU  - Lee HG
AD  - Department of Pediatrics, Chonnam National University Medical School & Children's 
      Hospital, Gwangju, Korea.
FAU - Yang, Eun Mi
AU  - Yang EM
AD  - Department of Pediatrics, Chonnam National University Medical School & Children's 
      Hospital, Gwangju, Korea.
FAU - Kim, Chan Jong
AU  - Kim CJ
AD  - Department of Pediatrics, Chonnam National University Medical School & Children's 
      Hospital, Gwangju, Korea.
LA  - eng
PT  - Journal Article
DEP - 20210930
PL  - Korea (South)
TA  - Ann Pediatr Endocrinol Metab
JT  - Annals of pediatric endocrinology & metabolism
JID - 101588279
PMC - PMC8505040
OTO - NOTNLM
OT  - Adverse events
OT  - Child
OT  - Graves' disease
OT  - Methimazole
COIS- Conflicts of interest No potential conflict of interest relevant to this article 
      was reported.
EDAT- 2021/10/07 06:00
MHDA- 2021/10/07 06:01
PMCR- 2021/09/01
CRDT- 2021/10/06 02:40
PHST- 2021/02/26 00:00 [received]
PHST- 2021/05/12 00:00 [accepted]
PHST- 2021/10/07 06:00 [pubmed]
PHST- 2021/10/07 06:01 [medline]
PHST- 2021/10/06 02:40 [entrez]
PHST- 2021/09/01 00:00 [pmc-release]
AID - apem.2142046.023 [pii]
AID - apem-2142046-023 [pii]
AID - 10.6065/apem.2142046.023 [doi]
PST - ppublish
SO  - Ann Pediatr Endocrinol Metab. 2021 Sep;26(3):199-204. doi: 
      10.6065/apem.2142046.023. Epub 2021 Sep 30.